INS and myeloid sarcoma: Studies conducted in people with pre-diabetes, hypertension and MS indicate a beneficial effect of eTRF on metabolic parameters (fasting glucose, fasting insulin, lipid profile, oxidative stress, hypertension, postprandial insulin) [153,154], even without total body fat mass reduction [155].